"Engineered Dual Binding Antibodies And Uses Thereof" in Patent Application Approval Process (USPTO 20240059769).

Předmět:	PATENT applications AMINO acid sequence IMMUNOGLOBULINS IMMUNOGLOBULIN class switching INNATE lymphoid cells
Zdroj:	Genomics & Genetics Weekly; 3/15/2024, p2660-2660, 1p
Abstrakt:	This patent application discusses the development of engineered dual binding antibodies that target interleukin 13 (IL-13) and thymic stromal lymphopoietin (TSLP), which are involved in allergic and inflammatory diseases such as asthma. The antibodies have specific amino acid sequences in their heavy chain variable regions (VH) and light chain variable regions (VL) that contribute to their binding properties. The invention provides various amino acid sequences for the VH and VL domains, as well as combinations of these domains. The antibodies have potential applications in the treatment of allergic and inflammatory conditions. [Extracted from the article]
Databáze:	Complementary Index
Externí odkaz:	Zobrazit plný text záznamu